Visudyne | QLT Inc

By: Q L T  09-12-2011

How it Works
Visudyne® slows or stops the progression of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular histoplasmosis.  Administration of Visudyne therapy involves the use of a specially designed diode laser that produces the low level, non-thermal (non-burning) light required to activate the drug. It is easily administered by practitioners and can be done in a physician's office in four steps.
Step oneVisudyne is administered to the patient intravenously for 10 minutes.
Step twoIn the bloodstream Visudyne attaches to lipoproteins which selectively carry the drug to abnormal vessels in the eye.
Step threeFive minutes after the infusion, Visudyne is activated by shining a red, non-thermal laser light into the patient's eye for 83 seconds.
Step fourOnce Visudyne is activated, the abnormal blood vessel cells are destroyed by the release of singlet oxygen, resulting in closure of the abnormal vessels and cessation of leakage.
Visudyne® is a registered trademark of Novartis AG

Other products and services from Q L T



Aczone currently has a label restriction that requires patients to be screened to detect if they are predisposed to a type of anemia (hemolytic anemia) due to a deficiency in a specific enzyme. Aczone is an aqueous topical gel containing 5% dapsone, an anti-inflammatory and anti-microbial drug.